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Abstract: (248 words; Limit 250 words) 
 
Aims: Prognostic models for hospitalised heart failure (HHF) were developed predominantly for 
patients of European origin in the United States of America; it is unclear whether they perform 
similarly in other health-care systems or for different ethnicities. We sought to validate published 
prediction models for HHF in the United Kingdom (UK) & Japan. 
Methods and Results: Patients in the UK (894) and Japan (3,158) were prospectively enrolled 
and similar in terms of sex (~60% men) and median age (~77 years). Models predicted that British 
patients would have a higher mortality than Japanese, which was indeed true both for in-hospital 
[4.8% vs 2.5%] and 180-day [20.7% vs 9.5%] mortality. The model c-statistics for the 
published/derivation [range 0.70-0.76] and Japanese [range 0.75-0.77] cohorts were similar and 
higher than for the UK [0.62-0.75] but models consistently over-estimated mortality in Japan. For 
in-hospital mortality, OPTIMIZE-HF performed best, providing similar discrimination in 
published/derivation, UK and Japanese cohorts [c-indices: 0.75 (0.74-0.77); 0.75 (0.68 - 0.81) and 
0.77 (0.70 - 0.83)], and least over-estimated mortality in Japan. For 180-day mortality, the c-
statistics for ASCEND-HF were similar in published/derivation [0.70] and UK [0.69 (0.64 - 0.74)] 
cohorts but higher in Japan [0.75 (0.71 - 0.79)]; calibration was good in the UK but again over-
estimated mortality in Japan.  
Conclusion: Calibration of published prediction models appear moderately accurate and unbiased 
when applied to British patients but consistently overestimate mortality in Japan. Identifying the 
reason why patients in Japan have a better than predicted prognosis is of great interest. 
 
Keywords: acute heart failure; hospitalised heart failure; mortality prediction; outcome; Japan
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Introduction 
 
 
The prevalence of heart failure is rising due to an ageing population and longer survival 
after the onset of cardiovascular diseases, including heart failure itself.1-4 Improvements in care 
have failed to stem a rising tide of heart failure related hospital admissions. Annually, heart failure 
is the primary reason for >200,000 admissions in Japan,2, 5 >80,000 in the United Kingdom (UK)6 
and about one million in the United States of America (USA).7 Despite advances in the 
management of chronic heart failure, mortality amongst patients hospitalized with worsening heart 
failure remains high and no intervention has been convincingly shown to improve outcome. 8-15 
Prognostic models for hospitalized heart failure (HHF) derived from surveys, registries, 
and randomized clinical trials have identified many variables that are associated with outcome. 16-
27 Knowing a patient’s risk may help guide management, including the intensity of follow-up, the 
urgency of advanced interventions or the need for palliative care. Moreover, some prognostic 
variables, such as renal function or serum potassium concentration, might be therapeutic targets. 
However, prognostic models have been developed primarily in patients of European origin and in 
the USA. It is unclear whether these published models predict outcome in other geographic 
regions with different health-care systems or other ethnic groups. Important regional differences 
exist not only in terms of health economy, medical infrastructure and management but also patient 
characteristics and their adherence to medical advice and lifestyle.28-31 Accordingly, we 
investigated the validity of five published HHF mortality prediction models for cohorts of patients 
enrolled in the UK and Japan. 
 
Methods 
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Data sources 
 
The UK HHF Cohort comprised registry data from two National Health Service (NHS) 
hospitals in London and one in Kingston-upon-Hull,32 each serving a local population of 
approximately 250,000 people and participating in the NHS England and Wales National Heart 
Failure Audit.6 Between 2011 and 2013, 894 patients were prospectively enrolled. Data were 
generally acquired within hours of admission. This was part of a national survey initiated by the 
NHS which provided ethical oversight. 
The WET-HF (WEst Tokyo Heart Failure) registry is an ongoing, multicenter, prospective 
observational registry of HHF in five large academic medical centers in metropolitan Tokyo (East 
Japan) that enrolled 2407 patients between 2011 and 2015.33 The NaDEF (National cerebral and 
cardiovascular center for acute DEcompensated heart Failure) registry enrolled 751 HHF patients 
prospectively at a single centre in Osaka (West Japan) between 2013 and 2015 based on the same 
inclusion/exclusion criteria as those in the WET-HF registry.34 Data in both registries were also 
generally acquired within hours of admission. The study protocols of the both the Japanese 
registries were approved by the respective institutional review boards, and were registered at the 
Japanese UMIN Clinical Trial Registration (UMIN000001171 and UMIN000017024, 
respectively). 
Patients were enrolled shortly after admission and mortality was recorded from admission 
providing it is reasonably accurate. 
 
Mortality prediction models and study population 
 
We carried out a detailed search using the MEDLINE/PubMed and EMBASE search 
engines and identified all the HHF mortality prediction models based on a specific search strategy 
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(Supplemental Appendix). This search strategy has been previously validated with high 
sensitivity and specificity for finding prediction research in MEDLINE.35 Among these 28 
models, five HHF models18, 19, 21, 26, 27 were chosen based on the available covariates available in 
both the UK and Japanese datasets (15 models were excluded due to lack of specific variables 
which are required to calculate the risk score and 8 models were excluded due to lack of 
availability of in-hospital mortality and 180 day outcomes) (Figure 1) for external validation in 
the UK and Japanese cohorts (Table 1 and Supplementary Tables S1-1, S2, S3-1 and S4-1).  
The HHF models identified were; 1) The Get With the Guidelines-Heart Failure (GWTG-
HF) risk score,18 2) The Acute Decompensated Heart Failure National Registry (ADHERE) 
model,21 3) The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with 
Heart Failure (OPTIMIZE-HF) risk score,19 4) The Acute Study of Clinical Effectiveness of 
Nesiritide in Decompensated Heart Failure (ASCEND-HF) risk score,27 5) The Outcomes of a 
Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-
CHF) risk score.26  
For each prediction model, we replicated the methods used by the original authors to 
calculate the predicted mortality for patients in the UK and Japanese cohorts. Racial origin was 
not collected but the vast majority of patients in the UK were of European origin and in Japan 
were Japanese. Accordingly, we did not use the ethnicity variable in the model, which applies 
mainly to people of African-American origin.  
In the UK, blood urea nitrogen (BUN) was missing in 41% of cases, reducing the 
population available for analysis of all models other than OPTIME-CHF, which used serum 
creatinine. Therefore, we repeated all other models, substituting BUN with serum creatinine using 
the formula shown in Supplemental Tables S1-2, S3-2 and S4-2. In the ADHERE registry we 
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used the coefficients of BUN, systolic BP, heart rate (HR) and age from their multivariable model 
to calculate the log-odds of in-hospital mortality (0.0212×BUN-0.0192×Systolic 
BP+0.0131×HR+0.0288×age-4.72) as shown in the original paper. The OPTIME-CHF risk score 
was developed to predict 60-day mortality but because 60-day mortality was not recorded for the 
UK, the score was applied for 90-day mortality in each data-set.  
41% (N=373) of UK patients had missing data on BUN and 27% (N=845) of Japanese 
patients did not have a record of New York Heart Association (NYHA) class. We therefore 
compared baseline characteristics and outcomes in British patients with and without BUN and in 
Japanese patients with and without a record of NYHA class. Survival status on days 30, 90 and 
180 day was recorded rather than the precise date of death. Some patients did not have data on 
survival status on day 30 (N=68 in the UK, N=792 in Japan), on day 90 (N=29 in the UK, N=844 
in Japan) or on day 180 (N=29 in the UK, N=906 in Japan) from the date of admission. 
 
Statistical Analysis 
 
Continuous variables are presented as mean ± standard deviation when normally 
distributed and otherwise as median and interquartile range (IQR). Comparison of differences 
between groups were made using the unpaired Student’s t-test or Mann-Whitney U test for 
continuous variables, and using chi-squared test or Fisher’s exact test for dichotomous variables, 
where appropriate. After defining predicted mortality (predicted probability of death) for each 
model using the risk scores or the log odds of mortality in the logistic regression model, we 
assessed discriminative performance and calibration for each model. Model discrimination was 
assessed by calculating the c-statistic with the area under the receiver operating characteristic 
curve. Calibration was assessed by plotting observed against predicted mortality, coefficient of 
 
 
Nagai T, et al. Validation of Risk Models in Decompensated Failure  
 
Page 8 of 23 
 
determination (large values of R2 indicating a better fit) and the Hosmer-Lemeshow goodness of 
fit statistic (smaller p-values (eg:- P<0.01) indicating a poor fit). A high R2 with a ‘significant’ p-
value suggests that the prediction model has precision but lacks accuracy, which might be 
improved by introducing a ‘correction factor’. All tests were two tailed, and a value of p <0.05 
was considered statistically significant. All analyses were performed with Stata MP 14.2 
(StataCorp., College Station, TX, USA). 
 
 
Results 
 
 
Cohort baseline characteristics 
 
Baseline characteristics for British (N=894) and Japanese (N=3158) patients are 
summarised in Table 2.  The median ages of British (76 [IQR 67-83] years) and Japanese (78 
[IQR 69-84] years) patients were similar and approximately 60% of each cohort was men. 
Compared to Japanese patients, British patients were more likely to have severe HF as evidenced 
by worse NYHA classification, lower systolic BP, lower serum sodium concentrations and higher 
serum concentrations of BUN and creatinine but British patients had higher body mass index. 
Median systolic BP in derivation cohorts of the ASCEND-HF and the OPTIME-CHF were 123 
and 120 mmHg, respectively, which were more similar to British compared to Japanese patients. 
Median serum creatinine concentrations of patients in the GWTG-HF, the ASCEND-HF and the 
OPTIME-CHF were also similar to the British cohort at 1.3, 1.2 and 1.4 mg/dL, respectively but 
lower amongst the Japanese (1.1mg/dL). Patients in the derivation cohorts and the UK were more 
likely to have a reduced LVEF than in Japan. The prevalence of ischemic heart disease was higher 
in each of the derivation cohorts (46-59%) and amongst British patients (48%) compared to the 
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Japanese (25%).  
Compared to Japanese patients, British patients had shorter LOHS (11 days vs 15 days P 
<0.001); 11.1% of British and 23.8% of Japanese patients were hospitalised for >30 days. British 
patients had higher in-hospital (4.8% vs 2.5%, P=0.001), 30-day (5.7% vs 2.6%, P <0.001; 90-day 
(13.6% vs 6.0% P <0.001) and 180-day mortality (20.7% vs 9.5%, P <0.001) (Table 3). Despite, a 
higher proportion of patients with HFrEF in the UK being discharged on guideline-directed 
medical therapy, post-discharge mortality was significantly lower in Japan (Table 3 and 
Supplementary Table S5). 
 
In-Patient Mortality 
Risk scores for in-patient mortality for the GWTG-HF, modified-GWTG-HF and 
OPTIMIZE-HF and the log odds for mortality of the ADHERE and modified-ADHERE were all 
higher for British patients (Table 3) consistent with their worse actual prognosis. Model c-
statistics were similar for the derivation and Japanese cohorts 18, 19, 21 but, apart from the 
OPTIMIZE-HF, performed less well in the UK (Table 4). In the UK, model discrimination 
improved when BUN was replaced with creatinine, possibly because this increased the number of 
patients available for analysis but for Japanese patients, replacing BUN with creatinine tended to 
reduce discrimination (Table 4). Overall, the OPTIMIZE-HF model, which uses creatinine rather 
than BUN, provided the best discrimination with remarkably similar c-statistics for the derivation 
19, British and Japanese cohorts (0.753, 0.752 and 0.767 respectively).  
Calibration coefficients for in-hospital mortality (Figure 2A-C) were also superior for the 
OPTIMIZE-HF compared to other models in both the UK (R2 = 0.76) and Japan (R2 = 0.91). Tests 
for goodness-of-fit consistently over-estimated mortality in all models for Japan, especially for 
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patients at lower risk. The OPTIMIZE-HF showed greater accuracy than other in-patient models 
for the UK and Japan. In Japan, substitution of BUN with creatinine reduced over-estimation of 
mortality leading to some improvement in fit with little effect on calibration coefficients (Figure 
3A and B). Substitution of BUN with creatinine had little influence on model calibration in the 
UK cohort (Figure 3A and B). 
 
 
Post-baseline Mortality at 30, 90 and 180 Days (Table 4, Figure 3 D-F). 
For 30-day mortality (the ASCEND-HF), the c-statistic for the Japanese and derivation 
cohorts were similar27 but lower in the UK. The model calibration coefficient was markedly 
higher for Japan (R2 = 0.82) compared to the UK (R2 = 0.12) but again over-estimated mortality in 
Japan. Substituting BUN with creatinine improved model precision in the UK but not Japan and 
improved calibration in the UK. 
For 90-day (the OPTIME-CHF) mortality, the c-statistic for Japanese patients was again 
similar to that of the derivation cohort26 but lower for British patients. Model coefficients were 
high for both cohorts but again over-estimated mortality in Japan; substituting BUN with 
creatinine had little effect on model performance for either cohort. 
For 180-day mortality, the ASCEND-HF model c-statistics were similar for the 
derivation27 and UK cohorts but higher for the Japanese. Model coefficients were high both for 
British (R2 = 0.96) and Japanese (R2 = 0.95) patients but again overestimated mortality in Japan. 
Substituting BUN with creatinine did not improve model performance. 
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Discussion 
 
This analysis suggests that at least some published models for predicting mortality in HHF, 
developed predominantly for patients of European origin enrolled in the USA, provide similar 
prediction for patients enrolled in our registries in Japan and the UK. Indeed, the ability of the 
models to predict mortality was somewhat greater for Japanese compared to British patients. This 
suggests that the variables contributing to these models maintain their relationship to outcome in 
diverse health care systems and ethnicities. However, the published models consistently over-
estimated mortality for HHF patients in Japan. These analyses should be confirmed and refined 
using other similar or larger data-sets internationally. 
For in-patient mortality, the OPTIMIZE-HF performed well, in terms of discrimination 
and calibration, in both the UK and Japan. This is remarkable, given the very different lengths of 
hospital stay in the UK and Japan compared to the USA.17, 19, 21, 36-40. Longer hospital stays expose 
patients to a prolonged period at risk of events, even if they might subsequently lead to lower 
post-discharge mortality. Interestingly, the OPTIMIZE-HF was the only model that used serum 
creatinine in preference to BUN as a measure of renal dysfunction and adopted serum sodium as a 
“U-shaped” risk variable with 140 mEq/L as the nadir of risk.19, 41 In the UK, improvement in the 
performance of in-patient and 30-day models by substituting BUN with creatinine might simply 
be attributed to the ability to include more patients in the analysis. In Japan, the effect of 
substituting BUN for creatinine in the GWTG-HF and the ADHERE in-patient models was 
complex; model discrimination declined slightly but model calibration improved somewhat for the 
GTWG-HF and over-estimation of mortality was reduced in both models. Model coefficients for 
the 90- and 180-day outcome models were high for both Japan and the UK but again consistently 
over-estimated mortality in Japan, which was a half to a quarter of that predicted. The high model 
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coefficients and consistently lower than predicted mortality for Japanese patients suggests that 
adding a variable to adjust for ethnicity might improve model calibration. In these longer-term 
models, substitution of BUN with creatinine had little effect on c-statistics or calibration and only 
modestly reduced over-estimation of mortality in Japan. The high model coefficients and 
consistently lower than predicted mortality for Japanese patients suggests that adding a variable to 
adjust for ethnicity might improve model calibration. 
Other models for HHF suggest that urea is a better marker of prognosis than creatinine.24 
which is consistent with the reduction in model-discrimination after substituting BUN with 
creatinine in Japan. However, the prognostic superiority of BUN may be modest and creatinine 
may serve almost as well.24 Indeed, serum urea, creatinine and their ratio may all provide additive 
prognostic information.24, 42 The reason why models using BUN rather than serum creatinine 
should demonstrate lower model accuracy (discrimination and calibration) in British patients is 
uncertain. Serum creatinine reflects muscle creatinine turnover, protein intake and renal 
function.43 BUN is also influenced by catabolic/anabolic balance but, in addition, a large 
proportion of urea is reabsorbed by the nephron especially if the patient is dehydrated or diuretic 
resistant. Greater muscle mass, differences in diet, the severity of congestion and use of higher 
doses of diuretics in the UK might all alter the relationships between BUN, creatinine and 
prognosis.  
Health care systems and hospitalisation threshold vary widely across world regions; hence 
it is likely that risk scores provide different performance in different populations. In the present 
study, British patients had a worse risk profile compared to the Japanese, including lower average 
systolic BP, left ventricular ejection fraction and serum sodium concentration and worse renal 
function, although age was similar and BMI higher. The observed mortality for HHF in the UK 
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was similar to that predicted by the models. In other words, although the mortality associated with 
HHF may be higher in the UK than in some other countries, this reflects sicker patients, perhaps 
due to a higher threshold for admission. On the other hand, Japanese patients not only appeared 
less sick, perhaps reflecting a lower threshold for admission, but also had a much lower than 
predicted mortality, especially amongst lower risk patients. However, it is possible that models 
derived from "sicker" populations in the US overestimate mortality in "less sick" patients 
independent of the world region. We can only speculate as to the reasons for the observed 
difference in mortality, which may include differences in management, patients’ adherence to 
medical advice and therapy, differences in culture, diet and lifestyle, heart failure aetiology, and 
genetics. Of note, mortality was higher in the UK despite a higher proportion of patients with 
HFrEF being discharged on guideline directed medical therapy (GDMT). One or more of the 
above differences might explain this anomaly. 
Adding a variable to reflect a greater variety of ethnic groups might improve the 
performance of existing models.39, 44 Alternatively, the influence of individual covariates could be 
reassessed in different ethnic groups and a new score developed but this might not capture the 
wider impact of ethnicity. 
Prognostic models that can be applied internationally would have considerable value not 
only for research but also for auditing the quality of care. First, transfer of patients to a tertiary 
centre with advanced care / heart failure therapies such as left ventricular assisted device and 
transplantation can be done based on existing models of accurate mortality prediction. Second, 
development of effective community services for heart failure, a major thrust in the UK, means 
that many patients who used to be admitted to hospital for care are now managed at home or in 
day-care facilities. Accordingly, patients admitted to hospital are often sicker and more likely to 
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die. The National Heart Failure Audit for England & Wales reported an in-patient mortality for 
32,991 HHF patients of 9.4% in 2013/14 (although < 3.0% if aged <65 years) which is a much 
higher mortality than reported in the USA (3.1% in 2010/2013)45 or Japan (6.4% in 2007/2011).28 
Until an international model to assess prognosis is developed it may be impossible to determine 
whether poor outcome for HHF in a country reflects a high or low quality of care. Rather than 
starting afresh, it seems better to build on existing models, some of which performed well in this 
analysis. Starting with a model and only adding variables that improve it substantially or simplify 
it is likely to lead to faster and more certain evolution than re-inventing a new model for each new 
patient cohort.24 
 
Limitations 
Our study population includes patients only from selected academic medical centres in 
Japan and Britain which may not be representative for the whole population. The mortality in our 
study populations was lower than that observed in the published national data in both countries. 
However, the difference in mortality between the two countries in our study is quite similar to 
difference in mortality observed in national data-sets (~40% higher mortality in UK compared to 
Japan). Validating prediction models in national data-sets is not currently possible since these do 
not record required variables including blood pressure and laboratory data. 
We used the same inclusion/exclusion HHF criteria for both Japanese registries (WET-HF 
and NaDEF) to increase the power of the analysis and generalizability of the results, although 
some differences in characteristics and outcomes were observed between these data-sets 
(Supplementary Table S6). 
Renal function and NYHA functional class are key determinants of prognosis in patients 
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with HF.46 The prediction models included in this analysis, with the exception of the OPTIMIZE-
HF, used BUN as a measure of renal dysfunction but this variable was missing in many patients 
from the UK. Moreover, NYHA functional class was often missing in Japanese patients. Some 
significant differences in baseline characteristics and outcomes were observed amongst patients 
who did or did not have these data recorded. Patients who had a missing BUN appeared sicker 
while patients without a record of NYHA class appeared less sick (Supplementary Table S7). 
However, supplementary analysis restricted only to patients without missing BUN and NYHA 
data and using BUN showed similar results to the main analysis (Supplementary Table S8 and 
Supplementary Figure S1). 
 Fortunately, serum creatinine was available in >99% allowing many more patients to be 
included in the analysis when used instead of BUN. This may explain why the OPTIMIZE-HF 
model performed well in the UK and why substitution of BUN with creatinine improved the 
performance of some models for the UK cohort. The failure of similar substitution to improve 
discrimination in Japanese patients supports the notion that the improvement in the c-statistic in 
the UK was due to the inclusion of more patients rather than creatinine being a superior prognostic 
marker. 
We excluded 23 published models from 28 identified mortality prediction models either 
because our data lacked specific variables that the models required or because they did not report 
on in-hospital or 180-day mortality. 
The OPTIME-CHF model was developed for 60-day mortality, but as only 90-day 
mortality was recorded in the UK, we used this time-frame instead. As most deaths occurring in 
the first 90-days will have occurred within 60-days, this is unlikely to make a major difference. 
The OPTIME-CHF and the ASCEND-HF models were developed on patients who 
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consented to participate in a randomized controlled trial. Such patients may not be 
epidemiologically representative and the effects of excluding patients who were not approached to 
participate or who declined is uncertain. 
 
Conclusions: 
 
 Our analysis shows that existing prediction models predominantly derived from USA 
population and healthcare system provide fairly good discrimination for mortality amongst 
patients with HHF in the UK and Japan but overestimate mortality in Japan. Existing models 
could provide the basis for a universal mortality prediction model for HHF but might require 
modification depending on ethnicity. Further external validation of prediction models in diverse 
health care systems should be considered prior to application in routine clinical practice. 
Identifying the reason why patients in Japan have a better than predicted prognosis would be of 
great interest. 
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Figure Legends 
 
 
Figure 1-- Search strategy for the published HHF mortality prediction models. AUC = area 
under the curve; HHF = hospitalised due to worsening symptoms and signs of heart failure. 
 
Figure 2-- Calibration plot. Predicted compared to observed mortality for the published models. 
The line shows the line of perfect calibration. Dots represent mortality for patients stratified by 
predicted mortality for each cohort. P-values are for Hosmer-Lemeshow goodness-of-fit tests. 
ADHERE = Acute Decompensated Heart Failure National Registry; ASCEND-HF = Acute Study 
of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure; GWTG-HF = Get With 
the Guidelines-Heart Failure; OPTIME-CHF = Outcomes of a Prospective Trial of Intravenous 
Milrinone for Exacerbations of Chronic Heart Failure; OPTIMIZE-HF = Organized Program to 
Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure. 
 
 
Figure 3-- Calibration plot for modified published prediction models substituting BUN with 
creatinine. Predicted compared to observed mortality for the published models. The line shows 
the line of perfect calibration. Dots represent mortality for patients stratified by predicted 
mortality for each cohort. P-values are for Hosmer-Lemeshow goodness-of-fit tests. Abbreviations 
as in Figure 2.  
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Supplemental Figure S 1-- Calibration plot, restricted only to patients without missing BUN 
(in the UK) and NYHA (in Japan) data. ADHERE = Acute Decompensated Heart Failure 
National Registry; ASCEND-HF = Acute Study of Clinical Effectiveness of Nesiritide in 
Decompensated Heart Failure; GWTG-HF = Get with the Guidelines-Heart Failure; OPTIME-
CHF = Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic 
Heart Failure. 
  
Table 1 Published Mortality prediction models and the variables imputed on those models 
 
 
 
 
 
 
 
 
ADHERE = Acute Decompensated Heart Failure National Registry; ASCEND-HF = Acute Study of Clinical 
Effectiveness of Nesiritide in Decompensated Heart Failure; BP = blood pressure; BUN = blood urea nitrogen; 
COPD = chronic obstructive pulmonary disease; GWTG-HF = Get With the Guidelines-Heart Failure; LVSD = 
left ventricular systolic dysfunction; NYHA = New York Heart Association; OPTIME-CHF = Outcomes of a 
Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure; OPTIMIZE-HF = 
Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure; SCr = serum 
creatinine; UK = United Kingdom; USA = United States of America; RCT= Randomized clinical tria 
Variables GWTG-HF ADHERE OPTIMIZE-HF ASCEND-HF OPTIME-CHF 
Reference 18 21 19 27 26 
Published year 2010 2005 2008 2015 2004 
Type of study Registry Registry Registry RCT RCT 
Number of patients 71,284 33,046 37,548 7,141 949 
Number of Hospitals 287 263 259 398 80 
Country USA USA USA #International USA 
Mortality Hospital  Hospital  Hospital  30-day & 180-day 60-day  
Age ✔ ✔ ✔ ✔ ✔ 
Systolic BP ✔ ✔ ✔ ✔ ✔ 
Sodium ✔ 
 
✔ ✔ ✔ 
*BUN ✔ ✔ 
 
✔ ✔ 
SCr   ✔   
Heart rate  ✔    
*Black race ✔ 
 
   
COPD ✔ 
 
 
  
LVSD   ✔   
Primary cause for 
admission (HF/other) 
  ✔   
NYHA Class IV    ✔ ✔ 
• Modified GWTG-HF score: *Race was not available in the UK patients; because the assigned score was 
very low (0-3) and around 3% of population in England is British black, we assigned score “3” in all UK 
patients. BUN was replaced with creatinine  
• Modified ASCEND-HF score: BUN replaced with creatinine  
• Modified OPTIME-CHF score: BUN replaced with creatinine  
*41.7% of patients in the UK had missing BUN value and hence was replaced with creatinine  
# North America (44.9%), Europe (20.8%), Asia Pacific (24.9%), South America (9.4%) 
 
 
 
  Table 2 Baseline characteristics 
Variable 
% Missing 
UK/Japan 
UK 
N=894 
Japan 
N=3158 
P-value 
Age, years 0.1/0.0 76 (67-83) 78 (69-84) <0.001 
Male sex, n (%) 0/6.8 555 (62) 1744 (59) 0.13 
BMI 18.1/8.6 28 (25-33) 23 (20-26) <0.001 
NYHA III or IV, n (%) 
2.7/26.8 
802 (92) 1889 (82) <0.001 
NYHA IV, n (%) 252 (29) 1077 (47) <0.001 
Systolic BP, mmHg 0.6/15.1 129 (110-149) 136 (118-159) <0.001 
Heart rate, /min 0.7/15.4 86 (72-106) 90 (72-110) 0.016 
LVEF ≤45%, % 12.6/18.7 560 (72) 1377 (54) <0.001 
Comorbidities, n (%)     
Ischemic heart disease 0/0 433 (48) 778 (25) <0.001 
Diabetes mellitus 0.1/0.1 297 (33) 1187 (38) 0.017 
Hypertension 0.1/0.2 512 (57) 2312 (73) <0.001 
COPD/Asthma 0/18.4 221 (25) 141 (5) <0.001 
Atrial fibrillation 0.6/18.4 374 (41) 1305 (51) <0.001 
Stroke 1.3/18.6 88 (10) 457 (18) <0.001 
Laboratory data     
Hemoglobin, g/dL 43.7/0.4 12.3 (10.9-13.6) 11.8 (10.1-13.3) <0.001 
Sodium, mEq/L 0.1/0.5 138 (135-141) 140 (137-142) <0.001 
Potassium, mEq/L 2.1/0.5 4.4 (4.0-4.8) 4.3 (3.9-4.7) <0.001 
BUN, mg/dL 41.7/0.5 24.7 (16.5-38.9) 22.7 (16.7-33.0) 0.004 
Creatinine, mg/dL 0.5/0.6 1.3 (1.0-1.7) 1.1 (0.8-1.5) <0.001 
eGFR, mL/min/1.73m2 0.5/7.3 52 (36-73) 66 (43-89) <0.001 
CRP, mg/dL 22.5/0.0 1.5 (0.5-3.5) 0.5 (0.1-1.8) <0.001 
Medications at discharge, n (%)  3158    
ACE-Is or ARBs 8.1/1.9 682 (83) 1945 (63) <0.001 
Beta blockers 8.1/1.9 640 (78) 2268 (73) 0.007 
MRAs 7.2/7.7 424 (51) 962 (33) <0.001 
Diuretics 6.5/7.3 748 (89) 2070 (71) <0.001 
Values are n (%) or median (interquartile range), unless otherwise indicated. 
ACE-I = angiotensin converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; BP = 
blood pressure; BUN = blood urea nitrogen; COPD = chronic obstructive pulmonary disease; CRP = C - 
reactive protein; eGFR = estimated glomerular filtration rate; LVEF = left ventricular ejection fraction; MRA = 
mineralocorticoid receptor antagonists; NYHA = New York Heart Association. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Digitalis 5.6/2.1 203 (24) 251 (8) <0.001 
Table 3 Risk score and classification, predicted probability of death, duration of hospital stay, and actual 
mortality 
Variable 
UK 
N=894 
Japan 
N=3158 
P-value 
Risk scores or log odds of mortality (for ADHERE) 
 GWTG-HF for In-hospital death    
  Score 45 ± 9 41 ± 8 <0.001 
  Predicted probability of death, % 8.1 6.6 - 
 Modified GWTG-HF for In-hospital death   
  Modified score 48 ± 9 46 ± 9 <0.001 
  Predicted probability of death, % 4.9 4.1 - 
 ADHERE for In-hospital death    
  Score -3.1 ± 0.9 -3.4 ± 0.9 <0.001 
  Predicted probability of death, % 8.0 7.0 - 
 Modified ADHERE for In-hospital death   
  Modified score -3.9 ± 0.7 -4.0 ± 0.7 0.008 
  Predicted probability of death, % 4.8 4.6 - 
 OPTIMIZE-HF for In-hospital death    
  Score 35 ± 8 34 ± 7 <0.001 
  Predicted probability of death, % 5.1 4.4 - 
 ASCEND-HF for 30-day death    
  Score 3 (2-5) 3 (2-4) <0.001 
  Predicted probability of death, % 5.6 5.2 - 
 Modified ASCEND-HF for 30-day death   
  Modified score 3 (2-5) 3 (2-4) <0.001 
  Predicted probability of death, % 5.6 5.0 - 
 OPTIME-CHF for 90-day death    
  Score 186 ± 45 173 ± 44 <0.001 
  Predicted probability of death, % 16.1 13.8 - 
 Modified OPTIME-CHF for 90-day death   
  Modified score 174 ± 38 164 ± 38 <0.001 
  Predicted probability of death, % 13.3 11.4 - 
 ASCEND-HF for 180-day death    
Values are n (%), or mean ± SD, or median (interquartile range), unless otherwise indicated. 
Abbreviations as in Table 1.  
 
  Predicted probability of death, % 23.7 20.7 - 
 Modified ASCEND-HF for 180-day death   
  Predicted probability of death, % 20.5 17.9 - 
Length of Hospital Stay, days 11 (7-18) 15 (10-24) <0.001 
Length of Hospital Stay >30 days, % 11.1 23.8 <0.001 
Actual mortality    
In-hospital 43 (4.8) 80 (2.5) <0.001 
 30-day  47 (5.7) 62 (2.6) <0.001 
90-day  118 (13.6) 138 (6.0) <0.001 
180-day 179 (20.7) 214 (9.5) <0.001 
 Other abbreviations as in Table 1. 
Table 4 Discriminative value of risk models 
 Derivation cohort UK Japan 
Models C-statistic (95% CI) C-statistic (95% CI) C-statistic (95% CI) 
In-hospital    
 GWTG-HF 0.75 0.669 (0.594 - 0.737) 0.771 (0.710 - 0.832) 
 Modified GWTG-HF  0.722 (0.653 - 0.791) 0.758 (0.696 - 0.820) 
 ADHERE 0.759 0.663 (0.590 - 0.735) 0.755 (0.694 - 0.816) 
 Modified ADHERE  0.695 (0.622 - 0.768) 0.689 (0.624 - 0.755) 
 OPTIMIZE-HF 0.753 (0.741-0.765) 0.752 (0.683 - 0.810) 0.767 (0.702 - 0.832) 
30-day     
 ASCEND-HF 0.75 0.619 (0.521 - 0.717) 0.750 (0.677 - 0.822) 
 Modified ASCEND-HF  0.661 (0.592 - 0.730) 0.731 (0.659 - 0.802) 
90-day     
 OPTIME-CHF 0.76 0.673 (0.607 - 0.739) 0.751 (0.706 - 0.796) 
 Modified OPTIME-CHF  0.701 (0.650 - 0.753) 0.730 (0.683 - 0.777) 
180-day     
 ASCEND-HF 0.70 0.689 (0.637 - 0.742) 0.748 (0.712 - 0.785) 
 Modified ASCEND-HF  0.689 (0.647 - 0.731) 0.734 (0.697 - 0.770) 
Figure 1   
Records identified through 
MEDLINE/PubMed 
(N = 1502) 
Additional records identified 
through Embase and hand search 
(N = 2985) 
Records after duplicates removed 
(N = 2840) 
Records screened 
(N = 2840) 
Records excluded 
Non-risk models 
Not focused on HHF 
Not focused on mortality only 
(N = 2795) 
Excluded abstract only 
(N = 21) 
Full-text articles assessed  
for eligibility 
(N = 24) 
No c-index or AUC 
(N = 1) 
Studies finally identified 
(N = 23) 
28 different  
mortality prediction models 
15 models required variables 
that were not available in our 
data-sets 
 
8 models did not report in-
hospital or 180-day mortality 
5 mortality prediction models 
for final analyses 
Figure 2   
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Supplementary Tables 
 
Supplementary Table S1-1 GWTG-HF score 
 
Age, yrs Score Heart rate, beats/min Score SBP, mmHg Score Sodium, mEq/L Score BUN, mg/dl Score Black race Score COPD Score
≤19 0 ≤79 0 50-59 28 ≤130 4 ≤9 0 Yes 0 Yes 2
20-29 3 80-84 1 60-69 26 131 3 10-19 2 No 3 No 0
30-39 6 85-89 3 70-79 24 132 3 20-29 4
40-49 8 90-94 4 80-89 23 133 3 30-39 6
50-59 11 95-99 5 90-99 21 134 2 40-49 8
60-69 14 100-104 6 100-109 19 135 2 50-59 9
70-79 17 ≥105 8 110-119 17 136 2 60-69 11
80-89 19 120-129 15 137 1 70-79 13
90-99 22 130-139 13 138 1 80-89 15
100-109 25 140-149 11 ≥139 0 90-99 17
≥110 28 150-159 9 100-109 19
160-169 8 110-119 21
170-179 6 120-129 23
180-189 4 130-139 25
190-199 2 140-149 27
≥200 0 ≥150 28  
BUN = blood urea nitrogen; COPD = chronic obstructive pulmonary disease; SBP = systolic blood pressure. 
 
 
Table S1-2 Modified GWTG-HF score 
 
Age, yrs Score Heart rate, beats/min Score SBP, mmHg Score Sodium, mEq/L Score SCr, mg/dl Score Black race Score COPD Score
≤19 0 ≤79 0 50-59 28 ≤130 4 0 0 Yes 0 Yes 2
20-29 3 80-84 1 60-69 26 131 3 0-0.49 2 No 3 No 0
30-39 6 85-89 3 70-79 24 132 3 0.50-0.74 4
40-49 8 90-94 4 80-89 23 133 3 0.75-0.99 6
50-59 11 95-99 5 90-99 21 134 2 1.00-1.24 8
60-69 14 100-104 6 100-109 19 135 2 1.25-1.49 9
70-79 17 ≥105 8 110-119 17 136 2 1.50-1.74 11
80-89 19 120-129 15 137 1 1.75-1.99 13
90-99 22 130-139 13 138 1 2.00-2.24 15
100-109 25 140-149 11 ≥139 0 2.25-2.49 17
≥110 28 150-159 9 2.50-2.74 19
160-169 8 2.75-2.99 21
170-179 6 3.00-3.24 23
180-189 4 3.25-3.49 25
190-199 2 3.50-3.74 27
≥200 0 ≥3.75 28  
COPD = chronic obstructive pulmonary disease; SBP = systolic blood pressure; SCr = serum creatinine. 
 
 
 
 
 
 
Supplementary Table S2 OPTIMIZE-HF score 
 
Age, yrs Score Heart rate, beats/min Score SBP, mmHg Score Sodium, mEq/L Score SCr, mg/dl Score Primary cause of admission Score LVSD Score
20 0 65 0 50 22 110 13 0 0 HF 0 No 0
25 2 70 1 60 20 115 11 0.5 2 Other 3 Yes 1
30 3 75 1 70 18 120 9 1 5
35 5 80 2 80 16 125 7 1.5 7
40 6 85 3 90 14 130 4 2 10
45 8 90 4 100 12 135 2 2.5 12
50 9 95 4 110 10 140 0 3 15
55 11 100 5 120 8 145 2 3.5 17
60 13 105 6 130 6 150 4
65 14 110 6 140 4 155 6
70 16 150 2 160 8
75 17 160 0 165 10
80 19 170 12
85 20
90 22
95 24  
HF = heart failure; LVSD = left ventricular systolic dysfunction; SBP = systolic blood pressure; SCr = serum 
creatinine. 
 
Supplementary Table S3-1 ASCEND-HF score 
 
Age, yrs Score SBP, mmHg Score Sodium, mEq/L Score BUN, mg/dl Score Dyspnea at rest Score
>70 1 <130 1 <138 1 >25 1 Yes 1
>80 2 <100 2 <134 2 >40 2 No 0
>80 3  
BUN = blood urea nitrogen; SBP = systolic blood pressure. 
 
 
Table S3-2 Modified ASCEND-HF score 
 
Age, yrs Score SBP, mmHg Score Sodium, mEq/L Score SCr, mg/dl Score Dyspnea at rest Score
>70 1 <130 1 <138 1 >1 1 Yes 1
>80 2 <100 2 <134 2 >2 2 No 0
>3 3  
SBP = systolic blood pressure; SCr = serum creatinine. 
 
 
 
 
Supplementary Table S4-1 OPTIME-CHF score 
 
Age, yrs Score SBP, mmHg Score Sodium, mEq/L Score BUN, mg/dl Score NYHA Class IV Score
20 0 80 94 115 79 5 10 No 0
30 8 90 86 120 69 10 20 Yes 23
40 17 100 77 125 59 15 30
50 25 110 69 130 49 20 40
60 33 120 60 135 30 25 50
70 41 130 51 140 20 30 60
80 50 140 43 145 10 35 70
90 58 150 34 150 0 40 80
160 26 45 90
170 17 50 100
180 9
190 0  
BUN = blood urea nitrogen; NYHA = New York Heart Association; SBP = systolic blood pressure. 
 
 
Table S4-2 Modified OPTIME-CHF score 
 
Age, yrs Score SBP, mmHg Score Sodium, mEq/L Score SCr, mg/dl Score NYHA Class IV Score
20 0 80 94 115 79 0 - No 0
30 8 90 86 120 69 0.4 20 Yes 23
40 17 100 77 125 59 0.8 30
50 25 110 69 130 49 1.2 40
60 33 120 60 135 30 1.6 50
70 41 130 51 140 20 2 60
80 50 140 43 145 10 2.4 70
90 58 150 34 150 0 2.8 80
160 26 3.2 90
170 17 3.6 100
180 9
190 0  
NYHA = New York Heart Association; SBP = systolic blood pressure; SCr = serum creatinine. 
 
 
 
 
 
 
 
 
 
 
 
 Values are n (%). 
ACE-I = angiotensin converting enzyme; ARB = angiotensin receptor blocker; LVEF = left ventricular ejection 
fraction; MRA = mineralocorticoid receptor antagonists. 
 
 Supplementary Table S5 Medications at discharge in patients with LVEF ≤45% 
Variable 
UK 
N=318 
Japan 
N=1148 
P-value 
Medications at discharge, n (%)     
ACE-Is or ARBs 257 (90) 784 (70) <0.001 
Beta blockers 243 (84) 938 (84) 0.82 
MRAs 185 (64) 455 (41) <0.001 
Diuretics 260 (90) 891 (80) <0.001 
Digitalis 99 (33) 112 (10) <0.001 
  Supplementary Table S6 Baseline characteristics and outcomes between Japanese databases 
Variable 
WET-HF 
N=2407 
NaDEF 
N=751 
P-value 
Age, years 78 (68-84) 78 (70-84) 0.98 
Male sex, n (%) 1295 (59) 449 (60) 0.74 
NYHA IV, n (%) 730 (45) 347 (51) 0.007 
Systolic BP, mmHg 137 (118-160) 135 (117-157) 0.38 
Heart rate, /min 90 (73-111) 88 (71-108) 0.015 
LVEF ≤45%, % 962 (50) 415 (64) <0.001 
Comorbidities, n (%)    
Ischemic heart disease 559 (23) 219 (29) <0.001 
Diabetes mellitus 914 (38) 273 (36) 0.43 
Hypertension 1760 (73) 552 (74) 0.91 
COPD/Asthma 109 (6) 32 (4) 0.085 
Atrial fibrillation 927 (51) 378 (50) 0.85 
Stroke 263 (14) 194 (26) <0.001 
Laboratory data    
Sodium, mEq/L 140 (137-142) 140 (138-142) 0.042 
Potassium, mEq/L 4.3 (3.9-4.7) 4.2 (3.8-4.6) 0.090 
BUN, mg/dL 22 (17-32) 24 (17-34) 0.011 
Creatinine, mg/dL 1.0 (0.8-1.5) 1.1 (0.9-1.6) <0.001 
Medications at discharge, n (%)     
ACE-Is or ARBs 1428 (60) 517 (70) <0.001 
Beta blockers 1742 (74) 526 (72) 0.27 
MRAs 634 (29) 328 (45) <0.001 
Diuretics 1482 (68) 588 (80) <0.001 
Digitalis 165 (7) 86 (12) <0.001 
Length of Hospital Stay, days 14 (9-22) 20 (14-28) <0.001 
Death    
In-hospital 64 (2.7) 16 (2.1) 0.42 
 30-day  49 (2.9) 13 (1.9) 0.17 
Values are n (%) or median (interquartile range), unless otherwise indicated. 
ACE-I = angiotensin converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; BP = 
blood pressure; BUN = blood urea nitrogen; COPD = chronic obstructive pulmonary disease; CRP = C - 
reactive protein; eGFR = estimated glomerular filtration rate; LVEF = left ventricular ejection fraction; MRA = 
mineralocorticoid receptor antagonists; NYHA = New York Heart Association. 
 
90-day  106 (6.5) 32 (4.7) 0.104 
180-day 170 (10.7) 44 (6.7) 0.003 
 Supplementary Table S7 Baseline characteristics and outcomes between included and excluded patients 
 UK  Japan  
Variable 
With BUN 
N=521 
Without BUN 
N=373 
P-value 
With NYHA 
N=2313 
Without NYHA 
N=845 
P-value 
Age, years 78 (71-84) 73 (60-82) <0.001 78 (68-84) 79 (70-85) <0.001 
Male sex, n (%) 336 (64) 219 (59) 0.079 1400 (61) 344 (55) 0.008 
BMI 28 (25-33) 28 (24-33) 0.84 23 (20-26) 23 (20-26) 0.035 
NYHA III or IV, n (%) 443 (88) 359 (98) <0.001 1889 (82) - - 
NYHA IV, n (%) 58 (12) 194 (53) <0.001 1077 (47) - - 
Systolic BP, mmHg 125(109-145) 133 (115-153) <0.001 136 (117-158) 138(120-160) 0.42 
Heart rate, /min 85 (71-104) 91 (73-110) 0.008 90 (72-110) 92 (73-112) 0.39 
LVEF ≤45%, % 318 (67) 242 (80) <0.001 1148 (54) 229 (53) 0.72 
Comorbidities, n (%)       
Ischemic heart disease 285 (55) 148 (40) <0.001 637 (28) 141 (17) <0.001 
Diabetes mellitus 179 (34) 118 (32) 0.41 824 (35) 373 (44) <0.001 
Hypertension 293 (56) 219 (59) 0.43 1572 (68) 740 (88) <0.001 
COPD/Asthma 125 (24) 96 (26) 0.55 125 (5) 16 (6) 0.75 
Atrial fibrillation 236 (46) 138 (37) 0.009 1180 (51) 125 (47) 0.19 
Stroke 53 (10) 35 (9) 0.61 406 (18) 51 (19) 0.65 
Laboratory data       
Sodium, mEq/L 138 
(135-140) 
139 
(136-141) 
<0.001 140 
(138-142) 
140 
(137-142) 
0.004 
Potassium, mEq/L 4.4 (4.0-4.8) 4.4 (4.1-4.9) 0.24 4.3 (3.9-4.7) 4.2 (3.8-4.6) <0.001 
BUN, mg/dL 25 (17-39) N/A N/A 23 (17-32) 23 (17-37) 0.17 
Creatinine, mg/dL 1.3 (1.0-1.7) 1.3 (0.9-1.7) 0.63 1.1 (0.8-1.5) 1.1 (0.7-1.7) 0.93 
Medications at 
discharge, n (%)  
      
ACE-Is or ARBs 379 (80) 303 (87) 0.007 1462 (65) 483 (58) <0.001 
Beta blockers 370 (78) 270 (78) 0.87 1684 (75) 584 (70) 0.008 
MRAs 243 (51) 181 (51) 0.87 787 (31) 165 (25) <0.001 
Diuretics 419 (88) 329 (92) 0.048 1765 (78) 305 (46) <0.001 
Values are n (%) or median (interquartile range), unless otherwise indicated. 
ACE-I = angiotensin converting enzyme; ARB = angiotensin receptor blocker; BMI = body mass index; BP = 
blood pressure; BUN = blood urea nitrogen; COPD = chronic obstructive pulmonary disease; CRP = C - 
reactive protein; eGFR = estimated glomerular filtration rate; LVEF = left ventricular ejection fraction; MRA = 
mineralocorticoid receptor antagonists; NYHA = New York Heart Association. 
Digitalis 143 (30) 58 (16) <0.001 209 (9) 42 (5) <0.001 
Length of Hospital Stay, 
days 
11 (7-18) 11 (6-17) 0.43 16 (11-24) 12 (7-21) <0.001 
Death       
In-hospital 43 (8.3) 0 (0.0) <0.001 61 (2.6) 19 (2.3) 0.54 
 30-day  27 (5.8) 20 (5.6) 0.90 50 (2.5) 12 (3.5) 0.26 
90-day  84 (16.6) 34 (9.5) 0.003 106 (5.4) 32 (9.6) 0.002 
180-day 122 (24.1) 57 (15.9) 0.003 169 (8.7) 45 (14.1) 0.002 
 Other abbreviations as in Table 1. 
 
 
 
 
 
 
 
 
 
 
Supplementary Table S8 Discriminative value of risk models, restricted only to patients without missing 
BUN (in the UK) and NYHA (in Japan) data 
 Derivation cohort UK (N=521) Japan (N=2313) 
Models C-statistic (95% CI) C-statistic (95% CI) C-statistic (95% CI) 
In-hospital    
 GWTG-HF 0.75 0.682 (0.593 - 0.771) 0.766 (0.700 - 0.832) 
 ADHERE 0.759 0.665 (0.572 - 0.757) 0.750 (0.684 - 0.816) 
 OPTIMIZE-HF 0.753 (0.741-0.765) 0.723 (0.640 - 0.806) 0.759 (0.689 - 0.830) 
30-day     
 ASCEND-HF 0.75 0.619 (0.521 - 0.717) 0.746 (0.670 - 0.822) 
90-day     
 OPTIME-CHF 0.76 0.674 (0.600 - 0.747) 0.735 (0.682 - 0.787) 
180-day     
 ASCEND-HF 0.70 0.676 (0.615 - 0.736) 0.733 (0.692 - 0.774) 
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